Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YJW7 | ISIN: DK0060257814 | Ticker-Symbol: 22Z
Tradegate
05.06.25 | 12:43
62,92 Euro
+0,80 % +0,50
1-Jahres-Chart
ZEALAND PHARMA A/S Chart 1 Jahr
5-Tage-Chart
ZEALAND PHARMA A/S 5-Tage-Chart
RealtimeGeldBriefZeit
62,3062,7813:12
62,2462,8213:12

Aktuelle News zur ZEALAND PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
DiZealand Pharma submits glepaglutide MAA for short bowel syndrome15
MoZealand Pharma Submits MAA In Europe For Glepaglutide In Short Bowel Syndrome5
MoZealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome101Press release - No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025...
► Artikel lesen
27.05.Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons9
24.05.Cantor Fitzgerald behält Overweight-Rating für Zealand Pharma-Aktien bei14
ZEALAND PHARMA Aktie jetzt für 0€ handeln
20.05.Deutsche Bank cuts Zealand Pharma stock target to DKK48526
19.05.Zealand Pharma Appoints Chief Development Officer9
19.05.Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer5
09.05.Zealand Pharma-Roche Obesity Drug Deal Now Effective After Satisfying All Conditions27
09.05.Zealand Pharma announces closing of collaboration and license agreement with Roche295Company announcement - No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 - Zealand Pharma A/S ("the Company" or "Zealand...
► Artikel lesen
08.05.Zealand Pharma reports Q1 results17
08.05.Zealand Pharma Q1 2025 slides: Roche partnership bolsters cash position amid rising R&D costs39
08.05.Zealand Pharma Announces Financial Results for the First Three Months of 2025314Company announcement - No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities...
► Artikel lesen
02.05.Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit51
28.04.PRESSESPIEGEL/Unternehmen: EVONIK, BAYER, VOLKSWAGEN, ZF FRIEDRICHSHAFEN, ZEALAND PHARMA/ROCHE1.098DJ PRESSESPIEGEL/Unternehmen Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires. EVONIK - Der Chef des Chemiekonzerns Evonik, Christian Kullmann...
► Artikel lesen
24.04.Zealand Pharma gains as trial for Roche-partnered obesity drug starts23
24.04.Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes241Press release - No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2...
► Artikel lesen
23.04.Zealand Pharma appoints Utpal Singh as Chief Scientific Officer3
19.04.Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons6
19.04.Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025748Company announcement - No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark...
► Artikel lesen
Seite:  Weiter >>
109 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1